The aim of this study is to formulate curcumin into Nanostructured-Lipid Carrier preparations as an effort to improve bioavailability of curcumin, determined its characterization and to study its antibacterial activity. The method used to synthesis curcumin-NLC is evaporation and diffusion of solvents  in the aqueous system and ultrasonication, oleic acid and cholesterol are used as liquid lipid and solid lipid matrices. Curcumin-NLC was characterized by parameters of polydispersity index (IP), particle size, potential zeta,  entrapment efficiency and drug loading.

The curcumin-NLC produced in this study had an average particle size of 17,4 nm, polidispersity index (IP) 0,574, zeta potential -63,43 mV, entrapment efficiency and drug-loading are 92,23% and 0,87% respectively. These results indicate that curcumin can be formulated as an NLC with good characteristics and potential to be developed as an effective drug delivery systems. The inhibition zone of curcumin-nlc against S.aureus and E.coli obtained from this study are 7,72 mm and 6,0 mm respectively, and minimum inhibition concentration (MIC) is 50%. 

Keywords: Antibacterial, Bioavailabilty, Curcumin, NLC

Aggarwal, B. B., Yuan, W., Li, S., & Gupta, S. C. (2013). Curcumin-free turmeric exhibits anti-inflammatory and anticancer activities: Identification of novel components of turmeric. Molecular Nutrition & Food Research, 57(9), 1529–1542.

Almoussalam, M. Claudia Moia, C. Zhu. 2015. Development of nanostructured lipid carrier for dacarbazine delivery. Int Nano Lett. 5:241–248.

Anand, P., Kunnumakkara, A. B., Newman, R. A., & Aggarwal, B. B. (2007). Bioavailability of Curcumin: Problems and Promises. Molecular Pharmaceutics, 4(6), 807–818.

Brooks, G.F. Carrol, K.C. Butel, J.S. Morse, S.A. 2010. Jawetz, Melnick, and Adelbergs Medical Microbiology 25th Edition. USA: McGraw-Hill Companies

Carmona-Ribeiro AM. Biomimetic nanoparticles: preparation, characterization and biomedical applications. Int J Nanomed 2010; 5: 249-59.

Chinsriwongkul, A. Chareanputtakhun, P. Ngawhirunpat, T. Rojanarata, T. Sila-on,W. Ruktanonchai, U. Opanasopit, P. 2011. Nanostructured Lipid Carriers (NLC) for parenteral delivery of an anticancer drug. AAPS PharmSciTech.

Choffness, E.R. David, A.R. Alison, M. 2010. Antibiotic Resistance. USA: The National Academic Press

Clinical and Laboratory Standards Institute (CLSI). 2014. Perfomance Standards for Antimicrobial Susceptibility Testing: Twenty-Fourth Informational Supplement. USA: Wayne, P.A.

Emami J, Rezazadeh M, Varshosaz J, Tabbakhian M, Aslani A. Formulation of LDL targeted nanostructured lipid carriers loaded with paclitaxel: A detailed study of preparation, freeze drying condition, and in vitro cytotoxicity. J Nanomater. 2012;2012(Article ID 358782):10 pages.

Facchi, S. P., Scariot, D. B., Bueno, P. V. A., Souza, P. R., Figueiredo, L. C., Follmann, H. D. M.,Martins, A. F. (2016). Preparation and cytotoxicity of N-modified chitosan nanoparticles applied in curcumin delivery. International Journal of Biological Macromolecules, 87, 237–245.

Fang, C.-L., A. Al-Suwayeh, S., & Fang, J.-Y. (2012). Nanostructured Lipid Carriers (NLCs) for Drug Delivery and Targeting. Recent Patents on Nanotechnology, 7(1), 41–55.

Greenwood. 1995. Antibiotics Susceptibility (Sensitivity) Test, Antimicrobial ant Chemoterapy. USA: Addison Westley Longman Inc

Hewlings, S., & Kalman, D. (2017). Curcumin: A Review of Its’ Effects on Human Health. Foods, 6(10), 92.

Jing, M. Yongzhong, D. Hong, Y. Xingguo, Z. Qian, L. Yuefeng, R. Mengdan, Z. Fuqiang, H. 2015. Improved cytotoxicity of paclitaxel loaded in nanosized lipid carriers by intracellular delivery. J Nanopart Res. 17:10-19.

Laine A-L, Huynh NT, Clavreul A, Balzeau J, Béjaud J, Vessieres A, et al. Brain tumour targeting strategies via coated ferrociphenol lipid nanocapsules. European Journal of Pharmaceutics and Biopharmaceutics. 2012;81(3):690-3.

Lollo G, Vincent M, Ullio-Gamboa G, Lemaire L, Franconi F, Couez D, et al. Development of multifunctional lipid nanocapsules for the co-delivery of paclitaxel and CpG-ODN in the treatment of glioblastoma. International Journal of Pharmaceutics. 2015;495(2):972-80.

Mun, S.H. Joung, D.K. Kim, Y.S. Kang, O.H. Kim, S.B. Seo, Y.S. Kim, Y.C. Lee, D.S. Shin, D.W. Kweon, K.T. and Kwon, D.Y. 2013. Synergistic Antibacterial Effect of Curcumin Against Methicillin-resistant Staphylococcus aureus. Phytomedicine. 20: 714-718

Ng, W. K., Saiful Yazan, L., Yap, L. H., Wan Nor Hafiza, W. A. G., How, C. W., & Abdullah, R. (2015). Thymoquinone-Loaded Nanostructured Lipid Carrier Exhibited Cytotoxicity towards Breast Cancer Cell Lines (MDA-MB-231 and MCF-7) and Cervical Cancer Cell Lines (HeLa and SiHa). BioMed Research International, 2015, 1–10.

Nidhin,M. Indumathy, R. Sreeram, K.J. and Nair,B,U. (2008). Synthesis of Iron Oxide Nnaoparticles of Narrow Size Distribution on Polysaccharide Templates. Buletin Materaial Scence. 31 (1), 93-96

Pillarisetti, S., Maya, S., Sathianarayanan, S., & Jayakumar, R. (2017). Tunable pH and redox-responsive drug release from curcumin conjugated γ -polyglutamic acid nanoparticles in cancer microenvironment. Colloids and Surfaces B: Biointerfaces, 159, 809–819.

Prasad, S., Gupta, S. C., Tyagi, A. K., & Aggarwal, B. B. (2014). Curcumin, a component of golden spice: From bedside to bench and back. Biotechnology Advances, 32(6), 1053–1064.

Ranjan AP, Mukerjee A, Helson L, Vishwanatha K. Scale Up, Optimization and Stability Analysis of Curcumin C3 Complex-Loaded Nanoparticles for Cancer Therapy, J. of Nanobiotech., 2012, 10(38); 1-18.

Rosli, N.A. Hasham, R. Aziz, A. Aziz, R. 2015. Formulation and characterization of nanostructured lipid carrier encapsulated Zingiber zerumbet oil using ultrasonication technique. Journal of Advanced Research in Applied Mechanics. 11(1):16-23.

Sawant KK, Dodiya SS. Recent advances and patents on solid lipid nanoparticles. Recent Pat Drug Deliv Form 2008; 2: 120-35.

Wahlang B., Pawar Y. B., Bansal A. K. (2011). Identification of permeability-related hurdles in oral delivery of curcumin using the CaCo-2 cell model. Eur. J. Pharm. Biopharm. 77 275–282.